| Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing L Rasche, SS Chavan, OW Stephens, PH Patel, R Tytarenko, C Ashby, ... Nature communications 8 (1), 268, 2017 | 350 | 2017 |
| Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations B Will, L Zhou, TO Vogler, S Ben-Neriah, C Schinke, R Tamari, Y Yu, ... Blood, The Journal of the American Society of Hematology 120 (10), 2076-2086, 2012 | 254 | 2012 |
| Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma L Rasche, E Angtuaco, JE McDonald, A Buros, C Stein, C Pawlyn, ... Blood, The Journal of the American Society of Hematology 130 (1), 30-34, 2017 | 216 | 2017 |
| Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma N Weinhold, C Ashby, L Rasche, SS Chavan, C Stein, OW Stephens, ... Blood, The Journal of the American Society of Hematology 128 (13), 1735-1744, 2016 | 216 | 2016 |
| IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells C Schinke, O Giricz, W Li, A Shastri, S Gordon, L Barreyro, T Bhagat, ... Blood, The Journal of the American Society of Hematology 125 (20), 3144-3152, 2015 | 179 | 2015 |
| Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma L Rasche, D Alapat, M Kumar, G Gershner, J McDonald, CP Wardell, ... Leukemia 33 (7), 1713-1722, 2019 | 135 | 2019 |
| Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis CJ Heuck, J Mehta, T Bhagat, K Gundabolu, Y Yu, S Khan, G Chrysofakis, ... The Journal of Immunology 190 (6), 2966-2975, 2013 | 125 | 2013 |
| Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma JE McDonald, MM Kessler, MW Gardner, AF Buros, JA Ntambi, S Waheed, ... Clinical Cancer Research 23 (8), 1981-1987, 2017 | 122 | 2017 |
| Aberrant DNA methylation in malignant melanoma C Schinke, Y Mo, Y Yu, K Amiri, J Sosman, J Greally, A Verma Melanoma research 20 (4), 253-265, 2010 | 111 | 2010 |
| The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma L Rasche, EJ Angtuaco, TL Alpe, GH Gershner, JE McDonald, RS Samant, ... Blood, The Journal of the American Society of Hematology 132 (1), 59-66, 2018 | 92 | 2018 |
| Long-term outcomes after autologous stem cell transplantation for multiple myeloma KK Nishimura, B Barlogie, F van Rhee, M Zangari, BA Walker, ... Blood advances 4 (2), 422-431, 2020 | 80 | 2020 |
| The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma S Thanendrarajan, E Tian, P Qu, P Mathur, C Schinke, F van Rhee, ... Haematologica 102 (9), e364, 2017 | 80 | 2017 |
| The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma EM Boyle, S Deshpande, R Tytarenko, C Ashby, Y Wang, MA Bauer, ... Nature communications 12 (1), 293, 2021 | 76 | 2021 |
| Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker SS Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, CK Stein, ... Blood cancer journal 7 (2), e535-e535, 2017 | 71 | 2017 |
| Signal transduction inhibitors in treatment of myelodysplastic syndromes L Bachegowda, O Gligich, I Mantzaris, C Schinke, D Wyville, T Carrillo, ... Journal of hematology & oncology 6, 1-11, 2013 | 62 | 2013 |
| Stem cell origin of myelodysplastic syndromes HK Elias, C Schinke, S Bhattacharyya, B Will, A Verma, U Steidl Oncogene 33 (44), 5139-5150, 2014 | 57 | 2014 |
| Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma FE Davies, A Rosenthal, L Rasche, NM Petty, JE McDonald, JA Ntambi, ... Haematologica 103 (6), 1047, 2018 | 54 | 2018 |
| Linked-in: design and efficacy of antibody drug conjugates in oncology J Feld, SK Barta, C Schinke, I Braunschweig, Y Zhou, A Verma Oncotarget 4 (3), 397, 2013 | 53 | 2013 |
| Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease M Mohan, A Buros, P Mathur, N Gokden, M Singh, S Susanibar, ... American Journal of Hematology 92 (8), 739-745, 2017 | 50 | 2017 |
| BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma EM Boyle, C Ashby, RG Tytarenko, S Deshpande, H Wang, Y Wang, ... Clinical Cancer Research 26 (10), 2422-2432, 2020 | 46 | 2020 |
